Your prediction
Thiogenesis Therapeutics Corp. Stock
A loss of -2.630% shows a downward development for Thiogenesis Therapeutics Corp..
Pros and Cons of Thiogenesis Therapeutics Corp. in the next few years
Pros
?
M***** P*******
?
S********** s********
?
G***** c******* t* c**********
Cons
?
W********* I********* f** t** n*** y****
?
B****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
News
Thiogenesis Reports Positive Interim Phase 2 Trial Results for MELAS and Announces Pipeline Advancements in Leigh Syndrome and Cystinosis
Trial achieved biological proof-of-concept, dose discovery and biomarker improvement
San Diego, California, November 4, 2025 – Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF)
Thiogenesis Receives Confirmatory Guidance on IMPD for Pediatric MASH Phase 2a Clinical Trial in Europe and Core Patent Granted in EU
San Diego, CA, June 25, 2025 – Thiogenesis Therapeutics, Inc. (TSXV: TTI | OTCQX: TTIPF), a clinical-stage biopharmaceutical company developing next-generation thiol-based therapies for